Evidence map›Paper›PMID 36541802›Full record

ArticleJournal of virology2023

Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control.

Adam Wedrychowski, Holly Anne Martin, Yijia Li, Sushama Telwatte, Gayatri Nikhila Kadiyala, Meghan Melberg, Behzad Etemad, Elizabeth Connick, Jeffrey M Jacobson, David M Margolis and 7 more

Abstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. HIV controllers: hope for a functional cure.Frontiers in immunology · 2025
    Review
  8. Viral and immune predictors of HIV posttreatment control.Current opinion in HIV and AIDS · 2025
    Review
  9. Article
  10. HIV-1 latency reversal agent boosting is not limited by opioid use.medRxiv : the preprint server for health sciences · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. HIV post-treatment controllers have distinct immunological and virological features.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Adam Wedrychowski *Department of Medicine, University of California, San Francisco, California, USA.
Holly Anne Martin *Department of Medicine, University of California, San Francisco, California, USA.
Yijia Li *Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-5300-0571
Sushama TelwatteDepartment of Medicine, University of California, San Francisco, California, USA.
Gayatri Nikhila KadiyalaDepartment of Medicine, University of California, San Francisco, California, USA.
Meghan MelbergDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Behzad EtemadDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Elizabeth ConnickDepartment of Medicine, University of Arizona, Tucson, Arizona, USA.
Jeffrey M JacobsonDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
David M MargolisUNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Daniel SkiestDepartment of Medicine, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.
Paul VolberdingDepartment of Medicine, University of California, San Francisco, California, USA.
Frederick HechtDepartment of Medicine, University of California, San Francisco, California, USA.
Steven DeeksDepartment of Medicine, University of California, San Francisco, California, USA.
Joseph K WongDepartment of Medicine, University of California, San Francisco, California, USA.
Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Steven A YuklDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-4578-9872

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jae M. Sevelius · 1988 to 2026
$93.6M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
HIV Reservoir Ecology of Viral Remission (PTC)R01AI150396 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LI, JONATHAN · 2020 to 2025
$5.4M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Investigating Mechanisms of HIV Persistence in the GutR01DK108349 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YUKL, STEVEN A · 2015 to 2019
$2.2M
Understanding HIV latency reversal and clearance of infected cells in vivoR01AI132128 · NIAID · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K, YUKL, STEVEN A · 2017 to 2021
$1.9M
HIV Reservoir Ecology of Viral Remission (PTC)R37AI150396 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Jonathan Li · 2026 to 2026
$868k
NIAID NIH HHS P01 AI169606NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI132128NIAID NIH HHS R37 AI150396NIAID NIH HHS T32 AI007387NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIDDK NIH HHS R01 DK108349NIDDK NIH HHS R01 DK120387
6 · The paper itself

Abstract

Posttreatment controllers (PTCs) are rare HIV-infected individuals who can limit viral rebound after antiretroviral therapy interruption (ATI), but the mechanisms of this remain unclear. To investigate these mechanisms, we quantified various HIV RNA transcripts (via reverse transcription droplet digital PCR [RT-ddPCR]) and cellular transcriptomes (via RNA-seq) in blood cells from PTCs and noncontrollers (NCs) before and two time points after ATI. HIV transcription initiation did not significantly increase after ATI in PTCs or in NCs, whereas completed HIV transcripts increased at early ATI in both groups and multiply-spliced HIV transcripts increased only in NCs. Compared to NCs, PTCs showed lower levels of HIV DNA, more cell-associated HIV transcripts per total RNA at all times, no increase in multiply-spliced HIV RNA at early or late ATI, and a reduction in the ratio of completed/elongated HIV RNA after early ATI. NCs expressed higher levels of the IL-7 pathway before ATI and expressed higher levels of multiple cytokine, inflammation, HIV transcription, and cell death pathways after ATI. Compared to the baseline, the NCs upregulated interferon and cytokine (especially TNF) pathways during early and late ATI, whereas PTCs upregulated interferon and p53 pathways only at early ATI and downregulated gene translation during early and late ATI. In NCs, viral rebound after ATI is associated with increases in HIV transcriptional completion and splicing, rather than initiation. Differences in HIV and cellular transcription may contribute to posttreatment control, including an early limitation of spliced HIV RNA, a delayed reduction in completed HIV transcripts, and the differential expression of the IL-7, p53, and TNF pathways.

Indexed as

HIV InfectionsRNA, ViralTranscriptomeHIV-1HumansInterferonsInterleukin-7Tumor Suppressor Protein p53InterferonsInterleukin-7RNA, ViralTumor Suppressor Protein p53analytic treatment interruptionARTcell-mediated immune responseHIV DNAHIV posttreatment controllershuman immunodeficiency virusnoncontrollersRNA splicingsplicingtranscriptiontranscriptional completiontranscriptional profiletreatment interruptionviremic suppression

Identifiers

PMID36541802
PMCPMC9888280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.